Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Long Term Data Presented at ESC 2010 Shed Further Light on the Benefit of the CYPHER(R) Sirolimus Drug-Eluting Stent Compared to the ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups Sep 2, 2010 |
10.7 KB |
|
|
BRIDGEWATER, N.J., Sep 02, 2010 (BUSINESS WIRE) -- Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-ri... |
|||
|
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study Aug 31, 2010 |
14.8 KB |
|
|
STOCKHOLM, Aug 31, 2010 (BUSINESS WIRE) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care1 for the prevention of recurrent venous thromboemboli... |
|||
|
CORDIS announces results of ten-year CYPHER® Sirolimus-eluting coronary stent follow-up Aug 31, 2010 |
30.6 KB |
|
|
Stockholm, Sweden - August 31st, 2010 - Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER® Sirolimus-el... |
|||
|
Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain Aug 30, 2010 |
17.4 KB |
|
|
Raritan, NJ - August 30, 2010 - Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation. In addition, this study compared oxycodone controlled release ... |
|||
|
DePuy Orthopaedics Voluntarily Recalls ASR(TM) Hip System Aug 26, 2010 |
9.9 KB |
|
|
WARSAW, Ind., Aug 26, 2010 /PRNewswire via COMTEX News Network/ -- DePuy Orthopaedics, Inc., announced it is voluntarily recalling the ASR(TM) XL Acetabular System and DePuy ASR(TM) Hip Resurfacing System used in hip replacement surgery due to the number of patients who required a second hip replacement procedure, called a revision surgery. The ma... |
|||
|
STELARA®Three-Year Efficacy and Safety Data Presented on Patients with Moderate to Severe Plaque Psoriasis Aug 9, 2010 |
21.9 KB |
|
|
Chicago, IL, August 9, 2010 - New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (... |
|||
|
Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration Jul 26, 2010 |
9.1 KB |
|
|
[Titusville, NJ, July 26, 2010] - Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in tr... |
|||
|
TMC278 Pivotal Phase 3 Clinical Trials Achieve Primary Objective Jul 22, 2010 |
10.4 KB |
|
|
VIENNA, July 22 /PRNewswire/ -- Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily ... |
|||
|
Johnson & Johnson Reports 2010 Second-Quarter Results: Jul 20, 2010 |
36.8 KB |
|
|
NEW BRUNSWICK, N.J., July 20, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%,... |
|||
|
Former McKinsey & Company Chairman and Managing Director Ian Davis Appointed to Johnson & Johnson Board of Directors Jul 19, 2010 |
6.0 KB |
|
|
NEW BRUNSWICK, N.J., July 19, 2010 /PRNewswire via COMTEX News Network/ -- Ian E.L. Davis, former Chairman and Worldwide Managing Director of McKinsey & Company, today was appointed to the Board of Directors of Johnson & Johnson (NYSE: JNJ), the world's most broadly based health care products company. Davis is currently Senior Partner and Director... |
|||
|
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice Jul 19, 2010 |
17.3 KB |
|
|
Raritan, NJ – July 19, 2010 – A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release (ER) tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release (CR) tablets. The study found tapentadol ER was associated with a lowe... |
|||
|
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results Jul 13, 2010 |
5.9 KB |
|
|
NEW BRUNSWICK, N.J., July 13, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 20, 2010, to review second-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President... |
|||
|
Johnson & Johnson Announces Definitive Agreement to Acquire Micrus Endovascular Jul 12, 2010 |
11.6 KB |
|
|
NEW BRUNSWICK, N.J. and SAN JOSE, Calif., July 12, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) and Micrus Endovascular Corporation (Nasdaq: MEND), a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke, today announced a definitive agreement whereby Micrus Endovasc... |
|||
|
Ethicon Endo-Surgery Completes Divestiture of Breast Care Business
to Devicor Medical Products Jul 12, 2010 |
6.3 KB |
|
|
Cincinnati, OH (July 12, 2010) - Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has completed the divestiture of its Breast Care business to Devicor Medical Products, Inc., a portfolio company of GTCR. Financial terms of the transaction are not being disclosed. Under the terms of the transaction, Devico... |
|||
|
McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-The-Counter (OTC) Products in the United States, Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago, and Jamaica Jul 8, 2010 |
84.2 KB |
|
|
Fort Washington, PA (July 8, 2010) - McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is recalling 21 lots of over-the-counter medicines. ... |
|||
|
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT Jun 28, 2010 |
6.5 KB |
|
|
RARITAN, N.J., June 28, 2010 /PRNewswire via COMTEX News Network/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the signing of a five-year collaboration agreement with the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Called TRANSCEND, the collaboration agreement will foster o... |
|||
|
Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes Jun 26, 2010 |
11.9 KB |
|
|
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 (SGLT2) inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a ... |
|||
|
McNeil Consumer Healthcare Jun 24, 2010 |
7.3 KB |
|
|
FORT WASHINGTON, PA (June 24, 2010) - McNeil Consumer Healthcare, division of McNeil-PPC, Inc., a Johnson & Johnson company, today announced that it does not anticipate having sources of supply before the end of 2010 for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility. Operations at the Fort W... |
|||
|
Biosense Webster Receives FDA Clearances for the CARTOXPRESS(TM) Software Module and LASSO(R) NAV Catheter for its CARTO(R) XP System Jun 23, 2010 |
10.3 KB |
|
|
DIAMOND BAR, Calif., Jun 23, 2010 (BUSINESS WIRE) -- Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today that the U.S. Food and Drug Administration (FDA) has cleared for marketing the CARTOXPRESS(TM) Software Module and the LASSO(R) NAV Circular Mapping Catheter ... |
|||
|
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters Agreement to Develop and Commercialize Antigen-Based Therapy for Type 1 Diabetes Jun 22, 2010 |
9.1 KB |
|
|
Raritan, NJ (June 22, 2010) - Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) announced today it has signed an exclusive agreement with Diamyd Medical AB, a Swedish publicly traded company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, to develop and commercialize their GA... |
|||
= add release to Briefcase
